Please read this page before participating in this activity. At the bottom of the page, select “I have read these instructions and understand them,” and then click “Begin Activity.”


Overview

CME Credit Available: Maximum of 6.0 AMA PRA Category 1 Credits™
Release Date: May 5, 2011
Expiration Date: May 6, 2012

This activity consists of audio and visual recording of 8 live presentations with Question-and-Answer. To receive CME credit, please read the overview and follow the link to the presentation.

To view presentation, the learner should click on a presentation title. The Webcast will open in a separate window. The learner may view as many presentations in this activity as he/she chooses. Learner agrees that slides are for webcast viewing only. He or she will not copy, alter, or change these Webcast presentations in any way.

Once 1 or more presentations have been reviewed, learners may link to the CME evaluation from a link at the top of the main index of presentations. This is required for credit. Instructions for the evaluation are found on that page.


Needs and Objectives

Upon completion of the IAS–USA viral hepatitis course, participants will be able to:

• Describe HCV replication and its impact on drug development and treatment strategies

• List key data from clinical trials of direct-acting antivirals in patients with HCV infection who are treatment naive or who have not responded to HCV treatment

• Discuss the mechanisms of HCV resistance

• Implement the treatment plans for HCV-infected patients that consider

  • Clinical trial data on the efficacy and safety of directly acting antivirals
  • Appropriate screening
  • Monitoring for and definition of response
  • Potential drug-drug interactions
  • Management of adverse effects of treatment
  • Data tha are still needed to be able to best utilize current and future HCV treatments
• Describe the principles of managing liver disease, including staging and recommendations for monitoring for hepatocellular carcinoma.

 

CME Credit

The IAS–USA is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The IAS–USA designates this internet enduring material activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who claimed CME credit for attending the live CME course on which this activity is based may not claim credit for participating in this activity.


Intended Audience

This online CME activity is designed for physicians and other health care practitioners who are experienced in the principles of complex chemotherapy (eg, antiretroviral therapy) and are actively treating or will be treating patients with HCV infection.


Webcast Faculty

Program Committee

Susanna Naggie, MD
Assistant Professor of Medicine
Duke University School of Medicine
Durham Veterans Affairs Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Marion G. Peters, MD
John V. Carbone, MD, Professor
Chief of Hepatology Research
University of California San Francisco
San Francisco, California

Robert T. Schooley, MD
Professor and Vice Chair
Department of Medicine
Head, Division of Infectious Diseases
University of California San Diego
La Jolla, California

David L. Thomas, MD, MPH
Professor of Medicine
Director, Division of Infectious Diseases
The Johns Hopkins University
Baltimore, Maryland

Speakers

Raymond T. Chung, MD
Professor of Medicine
Harvard Medical School
Director of Hepatology
Vice Chief of Gastroenterology
Massachusetts General Hospital
Boston, Massachusetts

Marshall J. Glesby, MD, PhD
Associate Professor of Medicine and Public Health
Medical Director, Cornell HIV Clinical Trials Unit
Weill Medical College of Cornell University
New York, New York

Susanna Naggie, MD
Assistant Professor of Medicine
Duke University School of Medicine
Durham Veterans Affairs Medical Center
Duke Clinical Research Institute
Durham, North Carolina

Marion G. Peters, MD
John V. Carbone, MD, Professor
Chief of Hepatology Research
University of California San Francisco
San Francisco, California

Charles M. Rice, PhD
Maurice R. and Corinne P. Greenberg Professor
Laboratory of Virology and Infectious Disease
Scientific and Executive Director
Center for the Study of Hepatitis C
The Rockefeller University
New York, New York

Michael S. Saag, MD
Professor of Medicine
Jim Straley Chair in AIDS Research
Director, Center for AIDS Research
University of Alabama at Birmingham
Birmingham, Alabama

Robert T. Schooley, MD
Professor and Vice Chair
Department of Medicine
Head, Division of Infectious Diseases
University of California San Diego
La Jolla, California

Kenneth E. Sherman, MD, PhD
Gould Professor of Medicine
Director, Division of Digestive Diseases
University of Cincinnati College of Medicine
Cincinnati, Ohio

David L. Thomas, MD, MPH
Professor of Medicine
Director, Division of Infectious Diseases
The Johns Hopkins University
Baltimore, Maryland

David L. Wyles, MD
Assistant Professor of Medicine
University of California San Diego
La Jolla, California

Disclosure of Financial Affiliations

In the interest of maintaining the independence of its continuing medical education (CME) activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education, the IAS–USA requires all persons with control of content (ie; faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they (or their spouses or partners) have had with commercial companies within the past 12 months of the date of this Web-based CME conference. Any conflicts of interest of those parties are resolved prior to the education activity being delivered.

Course Faculty and Staff

Below are the disclosures of financial relationships of the faculty and program staff of this Web-based CME conference.

* Dr Chung has received grants and research support from Gilead Sciences, Inc, Mass BioLogics, Merck & Co, Inc/Schering-Plough Corp, Pfizer Inc, Roche, and Romark Laboratories, LC. (Updated 03/24/11)

* Dr Glesby has received grants and research support awarded to Weill Cornell Medical College from Pfizer Inc, and has served as a consultant to Bristol-Myers Squibb and Pfizer Inc. (Updated 03/26/11)

* Dr Naggie has served as a scientific advisor to Vertex Pharmaceuticals, Inc. (Updated 03/25/11)

* Dr Peters has served as a consultant to Merck & Co, Inc, Roche, and Vertex Pharmaceuticals, Inc. She has served as a scientific advisor to Clinical Care Options. (Updated 03/11/11)

Dr Rice has served as a consultant or scientific advisor to Genentech Inc, GlaxoSmithKline, iTherX, Inc, Merck & Co, Inc, and Novartis Vaccines & Diagnostics. He is a major stock shareholder for APATH, LLC. (Updated 04/08/11)

* Dr Saag has received grants and research support from or has been a scientific advisor to Ardea Biosciences, Inc, Avexa Ltd, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Merck & Co, Inc, Pain Therapeutics, Inc, Pfizer Inc, Tibotec Therapeutics, Vertex Pharmaceuticals, Inc, and ViiV Healthcare (Updated 02/25/11)

* Dr Schooley has served as a consultant to Gilead Sciences, Inc, GlaxoSmithKline, Inhibitex, Inc, Johnson & Johnson Services, Inc, Merck & Co, Inc, Santaris Pharma, Tobira Therapeutics, and Laboratory Corporation of America. He has stock options for Achillion Pharmaceuticals, Inc. (Updated 03/24/11)

* Dr Sherman has served as a consultant or scientific advisor to Boehringer Ingelheim Pharmaceuticals, Inc, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Inc, Regulus, SciClone, Three Rivers, and Vertex Pharmaceuticals, Inc. He has served on data and safety monitoring boards and endpoint adjudication committees for MedPace, Pfizer Inc, and Tibotec Therapeutics. He has received fees or royalties for written enduring materials, internet activities, and audiovisual activities from UpToDate. (Updated 03/24/11)

* Dr Thomas has received grants and research support from Gilead Sciences, Inc, and Merck & Co, Inc. He served as a scientific advisor to Merck & Co, Inc. (Updated 03/24/11)

* Dr Wyles has received grants awarded to the University of California San Diego from Merck & Co, Inc, and Vertex Pharmaceuticals. He also served as a consultant to Merck & Co, Inc. (Updated 02/25/11)

* IAS-USA Viral Hepatitis Advisory Board member. Members of the Advisory Board are not compensated for their role in governing/overseeing the hepatitis efforts of the IAS-USA.

Additional Advisory Board member:

Charles W. Flexner, MD
Professor of Medicine, Pharmacology, and International Health
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Dr Flexner has served as a scientific advisor to Bristol-Myers Squibb, Merck & Co, Inc, Tibotec Therapeutics, and Virostatistics LLC. (Updated 03/24/11)

IAS–USA CME Staff

Donna M. Jacobsen, Executive Director, has no relevant financial affiliations to disclose (Updated 04/11/11).

Gloria L. Balderas, CME Project Associate, has no relevant financial affiliations to disclose. (Updated 04/11/11)

Cristin M. Toth, CME Project Associate, has no relevant financial affiliations to disclose. (Updated 04/11/11)

Grant Support

This Webcast activity is sponsored by the IAS–USA.

Funding for this Webcast and on the live activity which this Webcast was based came from the following commercial companies:

MAJOR SUPPORTERS
Abbott Laboratories
Merck & Co, Inc
Vertex Pharmaceuticals, Inc

Discussion of Investigational or Unapproved Usage

This activity presents an update on new research that may involve the use of investigational or unapproved drugs and therapies. Participants should consult the product information and other resources for comprehensive information on drugs and therapies discussed in the cases. The views and opinions expressed herein are those of the faculty and do not necessarily represent the opinions or recommendations of the IAS–USA.


Contact Information

If you have any questions about this Web-based CME conference activity, please contact the IAS–USA:

IAS–USA
425 California Street
Suite 1450
San Francisco, CA 94104-2120
Telephone: 415-544-9400
Fax: 415-544-9401
E-mail: registration2011@iasusa.org

I have read these instructions and understand them.